Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

LaQuisa C Hill

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
NEJM Evidence|May 28, 2024
An Assessment of CAR-T Cell Therapy Utilization among Racial and Ethnic Minority PatientsLaQuisa C Hill, Melody Smith
Blood|January 6, 2022
COVID-specific T's may offset therapeutically endangered B'sLaQuisa C Hill, Premal D Lulla
Hematology/Oncology Clinics of North America|June 25, 2023
Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell LymphomasIbrahim N Muhsen, LaQuisa C Hill, Carlos A Ramos
Current Opinion in Immunology|November 20, 2021
Beyond CD19 CAR-T cells in lymphomaWingchi K Leung, Adanma Ayanambakkam, Helen E Heslop, et al.
Clinical Advances in Hematology & Oncology : H&O|June 1, 2018
The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphomaPremal D Lulla, LaQuisa C Hill, Carlos A Ramos, et al.
Transplantation and Cellular Therapy|September 14, 2024
Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantIbrahim N Muhsen, Kristen E Shaver, Tao Wang, et al.
Leukemia & Lymphoma|July 19, 2021
Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based studySamer Al Hadidi, Deepa Dongarwar, Hamisu M Salihu, et al.
Blood|January 19, 2024
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemiaWingchi K Leung, Alejandro G Torres Chavez, Matthew French-Kim, et al.
Bone Marrow Transplantation|August 26, 2024
Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host diseaseCurtis M Marcoux, Amin M Alousi, Jin Im, et al.
Cell Reports. Medicine|July 10, 2024
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicityRoyce Ma, Mae Woods, Phillip Burkhardt, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
NEJM Evidence|May 28, 2024
An Assessment of CAR-T Cell Therapy Utilization among Racial and Ethnic Minority PatientsLaQuisa C Hill, Melody Smith
Blood|January 6, 2022
COVID-specific T's may offset therapeutically endangered B'sLaQuisa C Hill, Premal D Lulla
Hematology/Oncology Clinics of North America|June 25, 2023
Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell LymphomasIbrahim N Muhsen, LaQuisa C Hill, Carlos A Ramos
Current Opinion in Immunology|November 20, 2021
Beyond CD19 CAR-T cells in lymphomaWingchi K Leung, Adanma Ayanambakkam, Helen E Heslop, et al.
Clinical Advances in Hematology & Oncology : H&O|June 1, 2018
The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphomaPremal D Lulla, LaQuisa C Hill, Carlos A Ramos, et al.
Transplantation and Cellular Therapy|September 14, 2024
Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantIbrahim N Muhsen, Kristen E Shaver, Tao Wang, et al.
Leukemia & Lymphoma|July 19, 2021
Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based studySamer Al Hadidi, Deepa Dongarwar, Hamisu M Salihu, et al.
Blood|January 19, 2024
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemiaWingchi K Leung, Alejandro G Torres Chavez, Matthew French-Kim, et al.
Bone Marrow Transplantation|August 26, 2024
Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host diseaseCurtis M Marcoux, Amin M Alousi, Jin Im, et al.
Cell Reports. Medicine|July 10, 2024
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicityRoyce Ma, Mae Woods, Phillip Burkhardt, et al.
Pageof 3